Home>>Peptides>> Amyloid β protein>>Amyloid-β (17-42) Peptide (human) (trifluoroacetate salt)

Amyloid-β (17-42) Peptide (human) (trifluoroacetate salt) (Synonyms: Aβ (17-42), LVFFAEDVGSNKGAIIGLMVGGVVIA)

Catalog No.GC42800

Amyloid-β (Aβ) (17-42) is a 26-residue fragment of the Aβ protein that is formed via post-translational processing of amyloid precursor protein (APP) by α- and γ-secretases.

Products are for research use only. Not for human use. We do not sell to patients.

Amyloid-β (17-42) Peptide (human) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
500μg
$341.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Amyloid-β (Aβ) (17-42) is a 26-residue fragment of the Aβ protein that is formed via post-translational processing of amyloid precursor protein (APP) by α- and γ-secretases. It has been found in postmortem cerebral cortex from patients with Alzheimer's disease that have diffuse amyloid plaques and in cerebellar preamyloid lesions in patients with Down's syndrome. In vitro, Aβ (17-42) forms amorphous aggregates that bind less thioflavin T than Aβ (1-40) and Aβ (1-42) . It is cytotoxic to SH-SY5Y and IMR-32 cells in a concentration-dependent manner and induces cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP) in SH-SY5Y cells when used at a concentration of 20 μM.

Reviews

Review for Amyloid-β (17-42) Peptide (human) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Amyloid-β (17-42) Peptide (human) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.